Register for our S/EIS Fund

In the 90’s, big Pharma kept all research functions within its corporate walls and since then innovation has been catalyzed through new models totally virtual, hybrid and open innovation.

In this o2h ChaiTime, we examined these models to determine if these are effective and how are they valued by investors and acquirers such as big pharma.

Dr. Matt Cooper Co-founder and CEO at Inflazome

Professor Matt Cooper is a scientific entrepreneur. He spends half his time in industry within companies that he has founded and half his time in academia. He is the Co-founder and former CEO of Inflazome Ltd, a company with a focus on developing drugs to treat inflammatory disease by targeting the inflammasome, recently acquired by Roche for $449m upfront.

Dr. Harren Jhoti President and CEO at Astex Pharmaceuticals

Harren Jhoti co-founded Astex in 1999 and was Chief Scientific Officer until November 2007 when he was appointed Chief Executive Officer. He was elected a Fellow of the Royal Society in 2018, the Royal Society of Chemistry in 2016, and of the Academy of Medical Sciences in 2015.

Professor Chas Bountra OBE Pro-Vice Chancellor for innovation at University of Oxford

Professor Chas Bountra is Pro Vice-Chancellor for Innovation at the University of Oxford. He is Professor of Translational Medicine in the Nuffield Department of Clinical Medicine and Associate Member of the Department of Pharmacology at the University of Oxford.

Sunil Shah CEO at o2h Group

Sunil Shah is a serial entrepreneur having begun a career in the Life Sciences team at PA Consulting group followed by co-founding two companies in the information technology and life sciences sector.

Register for Invitations